Matches in Wikidata for { <http://www.wikidata.org/entity/Q98947556> ?p ?o ?g. }
Showing items 1 to 31 of
31
with 100 items per page.
- Q98947556 description "artículu científicu espublizáu en setiembre de 2020" @default.
- Q98947556 description "scientific article published on 03 September 2020" @default.
- Q98947556 description "wetenschappelijk artikel" @default.
- Q98947556 description "наукова стаття, опублікована 3 вересня 2020" @default.
- Q98947556 name "Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma" @default.
- Q98947556 name "Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma" @default.
- Q98947556 type Item @default.
- Q98947556 label "Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma" @default.
- Q98947556 label "Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma" @default.
- Q98947556 prefLabel "Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma" @default.
- Q98947556 prefLabel "Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma" @default.
- Q98947556 P1433 Q98947556-2F01BD8F-F30D-412A-99A7-A5A606AF8377 @default.
- Q98947556 P1476 Q98947556-6B5FFB6C-5779-4FDF-A63D-96A32CB9C403 @default.
- Q98947556 P2093 Q98947556-45CE13AD-73C4-4966-9214-B88FFC4DBC01 @default.
- Q98947556 P2093 Q98947556-6D8672DA-AC39-4FDE-8CC8-3B659607B1C4 @default.
- Q98947556 P31 Q98947556-B8DEA584-5138-4AA2-BE1B-A8E6616BCB37 @default.
- Q98947556 P356 Q98947556-CAE992A3-6631-4414-BF5F-1199538A0CBB @default.
- Q98947556 P50 Q98947556-55F39E20-9C82-4AE8-9BFE-DCD1E9CC0FAB @default.
- Q98947556 P577 Q98947556-6095FC6D-B320-45E7-8DF3-297CCE03A07E @default.
- Q98947556 P698 Q98947556-00F5B649-7988-47AD-9605-184286C893E6 @default.
- Q98947556 P356 S00520-020-05726-0 @default.
- Q98947556 P698 32885313 @default.
- Q98947556 P1433 Q15766919 @default.
- Q98947556 P1476 "Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide"" @default.
- Q98947556 P2093 "James E Herndon" @default.
- Q98947556 P2093 "Mallika P Patel" @default.
- Q98947556 P31 Q13442814 @default.
- Q98947556 P356 "10.1007/S00520-020-05726-0" @default.
- Q98947556 P50 Q92804455 @default.
- Q98947556 P577 "2020-09-03T00:00:00Z" @default.
- Q98947556 P698 "32885313" @default.